CryoSave continues its European expansion through a partnership with the company Innovatsiyni Tekhnologiyi, based in Kiev.
Amsterdam, The Netherlands - 9 October 2017
Increasing number of families throughout the world are choosing to store stem cells from the umbilical cord blood and umbilical cord tissue of their newborn children.
CryoSave is now present in the Ukrainian market. Thanks to a partnership with Innovatsiyni Tekhnologiyi led by founders Sergiy Yaremenko, Natalya Sudakova and Igor Palyvoda, a new professional channel will enhance sustainability and strengthen leadership position in Europe.
CryoSave office is located in the Novopecherskie Lipki residential complex in the historical, cultural and business center of Kiev.
With a population of 42,5 million, 450 000 labors per year and 1,53 deliveries for a woman, Ukraine constitutes a strong market for the cryopreservation of umbilical cord blood and cord tissue. Kiev is the capital and about 3 million people live there with about 97 babies born every day.
Today, Ukrainian families entrust the future of their child to a reliable, experienced, authoritative and world-renowned stem cells bank. The financial opportunities of the Ukrainian "middle class "meet the criteria of European service, reliability and confidence in the quality of the bank's storage.
Established in 2000, CryoSave is the most experienced, reliable and technologically advanced family Stem Cell Bank in Europe, fully authorized for autologous and allogeneic transplantations by the Swiss State Agency for therapeutic products and accredited as a licensed Organ and Tissue Establishment.
The exclusive partnership with Innovatsiyni Tekhnologiyi will be used as a point of contact and sale for potential CryoSave customers. The agent will train medical staff to collect the cord blood according to CryoSave's logistics procedures.
CryoSave is led by a team of medical and scientific professionals, ensuring the highest quality of processes from collection through to storage. The dedicated medical professional presence in all countries they operate, provides clients and partners with direct expert communication and support.
CEO of Esperite Group, Frédéric Amar says: This agreement with Innovatsiyni Tekhnologiyi is good opportunity for us to widen our sales capabilities eastwards and gain market share in Ukraine.
Amsterdam, The Netherlands - 9 October 2017
About ESPERITE
ESPERITE is a diversified biotech global group leader in regenerative and precision medicine. Established in 2000, the holding group is headquartered in the Netherlands, listed at Euronext Amsterdam and Paris and operational in over 30 countries.
ESPERITE transforms the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com, www.genoma.com and www.cryo-save.com.
